Effects of Gender-Affirming Hormone Therapy on Insulin Sensitivity and Incretin Responses in Transgender People
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The long-term influences of sex hormone administration on insulin sensitivity and incretin hormones are controversial. We investigated these effects in 35 transgender men (TM) and 55 transgender women (TW) from the European Network for the Investigation of Gender Incongruence (ENIGI) study. RESEARCH DESIGN AND METHODS: Before and after 1 year of gender-affirming hormone therapy, body composition and oral glucose tolerance tests (OGTTs) were evaluated. RESULTS: In TM, body weight (2.8 ± 1.0 kg; P < 0.01), fat-free mass (FFM) (3.1 ± 0.9 kg; P < 0.01), and waist-to-hip ratio (−0.03 ± 0.01; P < 0.01) increased. Fasting insulin (−1.4 ± 0.8 mU/L; P = 0.08) and HOMA of insulin resistance (HOMA-IR) (2.2 ± 0.3 vs. 1.8 ± 0.2; P = 0.06) tended to decrease, whereas fasting glucose (−1.6 ± 1.6 mg/dL), glucose-dependent insulinotropic polypeptide (GIP) (−1.8 ± 1.0 pmol/L), and glucagon-like peptide 1 (GLP-1) (−0.2 ± 1.1 pmol/L) were statistically unchanged. Post-OGTT areas under the curve (AUCs) for GIP (2,068 ± 1,134 vs. 2,645 ± 1,248 [pmol/L] × min; P < 0.01) and GLP-1 (2,352 ± 796 vs. 2,712 ± 1,015 [pmol/L] × min; P < 0.01) increased. In TW, body weight tended to increase (1.4 ± 0.8 kg; P = 0.07) with decreasing FFM (−2.3 ± 0.4 kg; P < 0.01) and waist-to-hip ratio (−0.03 ± 0.01; P < 0.01). Insulin (3.4 ± 0.8 mU/L; P < 0.01) and HOMA-IR (1.7 ± 0.1 vs. 2.4 ± 0.2; P < 0.01) rose, fasting GIP (−1.4 ± 0.8 pmol/L; P < 0.01) and AUC GIP dropped (2,524 ± 178 vs. 1,911 ± 162 [pmol/L] × min; P < 0.01), but fasting glucose (−0.3 ± 1.4 mg/dL), GLP-1 (1.3 ± 0.8 pmol/L), and AUC GLP-1 (2,956 ± 180 vs. 2,864 ± 93 [pmol/L] × min) remained unchanged. CONCLUSIONS: In this cohort of transgender persons, insulin sensitivity but also post-OGTT incretin responses tend to increase with masculinization and to decrease with feminization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“A HOMA index was calculated using: HOMA of insulin resistance (HOMA-IR) 5 (glucose [mg/dL] 3 insulin [mg/dL])/405 (31).”
MethodDing, E. L., Song, Y., Malik, V. S., & Liu, S. (2006) · JAMA · doi:10.1001/jama.295.11.1288 · Cited by 1,354
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · cited 1×
“type 2 diabetes in most (20–23), but not all (24,25), reports.”
BackgroundSelf-citationFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · cited 1×
“1,400 subjects with a large range of BMIand insulin sensitivity suggested that post-OGTT GLP-1 response was higher in women than in men, but this difference was lostwith increasing insulin resistance (39).”
BackgroundBasaria, S., Harman, S. M., Travison, T. G., Hodis, H., Tsitouras, P., Budoff, M., Pencina, K. M., Vita, J., Dzekov, C., Mazer, N. A., et al. (2015) · JAMA · doi:10.1001/jama.2015.8881 · Cited by 268
Impaired regulation of the incretin effect in patients with type 2 diabetes
Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219
O'Sullivan, A. J., Crampton, L. J., Freund, J., & Ho, K. K. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2773 · Cited by 210
Gao, H., Bryzgalova, G., Hedman, E., Khan, A., Efendic, S., Gustafsson, J.-A., & Dahlman-Wright, K. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0012 · Cited by 179
Defreyne, J., Vantomme, B., Van Caenegem, E., Wierckx, K., De Blok, C. J. M., Klaver, M., Nota, N. M., Van Dijk, D., Wiepjes, C. M., Den Heijer, M., et al. (2018) · Andrology · doi:10.1111/andr.12485 · Cited by 114 · cited 1×
“free testosterone, sex hormone–binding globulin, and albumin were assessed as described previously (30).”
MethodIncretin levels in polycystic ovary syndrome
Vrbikova, J., Hill, M., Bendlova, B., Grimmichova, T., Dvorakova, K., Vondra, K., & Pacini, G. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0097 · Cited by 81 · cited 1×
“type 2 diabetes in most (20–23), but not all (24,25), reports.”
BackgroundNeto, W. K., Gama, E. F., Rocha, L. Y., Ramos, C. C., Taets, W., Scapini, K. B., Ferreira, J. B., Rodrigues, B., & Caperuto, É. (2015) · AGE · doi:10.1007/s11357-014-9742-0 · Cited by 64
Auer, M. K., Cecil, A., Roepke, Y., Bultynck, C., Pas, C., Fuss, J., Prehn, C., Wang-Sattler, R., Adamski, J., Stalla, G. K., et al. (2016) · Scientific Reports · doi:10.1038/srep37005 · Cited by 54 · cited 1×
“(33,35,37), but never improving, insulin sensitivity after both feminization and masculinization, usually after short-term Table 1—Antropometric and laboratory values at baseline and after 1 year of sex hormone administration”
BackgroundSelf-citationLapauw, B., Ouwens, M., ′t Hart, L. M., Wuyts, B., Holst, J. J., T'Sjoen, G., Kaufman, J.-M., & Ruige, J. B. (2010) · Diabetes Care · doi:10.2337/dc10-0515 · Cited by 32
Self-citation
Cited by
Streed, C. G., Beach, L. B., Caceres, B. A., Dowshen, N. L., Moreau, K. L., Mukherjee, M., Poteat, T., Radix, A., Reisner, S. L., Singh, V., et al. (2021) · Circulation · doi:10.1161/cir.0000000000001003 · Cited by 295
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
“A recent longitudinal analysis in transgender individuals revealed significant changes in metabolic profiles both in transgender women and men [58], suggesting potential implications to their NAFLD risk.”
BackgroundKaralexi, M. A., Georgakis, M. K., Dimitriou, N. G., Vichos, T., Katsimpris, A., Petridou, E. T., & Papadopoulos, F. C. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104721 · Cited by 41
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
“Moreover, as gender-affirming hormone therapy has also been shown to lead to altered metabolic profiles [37], but little is known about the impact of such therapies on MAFLD development, in vitro models might prove useful to gain further insights on this topic.”
Background
Metadata
- Authors
- Shadid, S., Abosi-Appeadu, K., De Maertelaere, A.-S., Defreyne, J., Veldeman, L., Holst, J. J., Lapauw, B., Vilsbøll, T., & T’Sjoen, G.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-11-18
- Volume
- 43
- Issue
- 2
- Pages
- 411-417
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2988177601
- Cited by
- 82
- References
- 16
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.